Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-26T04:57:19.072Z Has data issue: false hasContentIssue false
  • English
  • Français

Intramyocardial administration of autologous bone marrow mononuclear cells in a critically ill child with dilated cardiomyopathy

Published online by Cambridge University Press:  27 October 2010

Aris Lacis  and
Andrejs Erglis
Aris Lacis
Affiliation:
Latvian Centre of Pediatric Cardiology, Children’s Hospital, Riga, Latvia
Andrejs Erglis*
Affiliation:
Latvian Centre of Cardiology, Paula Stradina Clinical University Hospital, Riga, Latvia
*
Correspondence to: Prof. A. Erglis, MD, PhD, Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, Pilsonu 13, LV-1002, Riga, Latvia. Tel: +371 67069379; Fax: +371 67069548; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Almost half of the children with symptomatic dilated cardiomyopathy receive a transplant or die within 2 years; however, cardiac stem cell transplantation has become a promising therapeutic option. The present case demonstrates for the first time, to our knowledge, the intramyocardial administration of autologous bone marrow mononuclear cells in a critically ill 4-month-old child with severe dilated cardiomyopathy. Left ventricular ejection fraction increased from 20% before stem cell transplantation to 41% at 4 months of follow-up.

Keywords

Cardiac insufficiencystem cellstransplantation
Type
Brief Reports
Information
Cardiology in the Young , Volume 21 , Issue 1 , February 2011 , pp. 110 - 112
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Boucek, MM, Edwards, LB, Keck, BM, et al. The registry of the international society for heart and lung transplantation: fifth official pediatric report, 2001 to 2002. J Heart Lung Transplant 2002; 21: 827–840.CrossRefGoogle ScholarPubMed
2. Matitiau, A, Perez-Atayde, A, Sanders, SP, et al. Infantile dilated cardiomyopathy: relation to outcome to left ventricular mechanics, hemodynamics, and histology at the time of presentation. Circulation 1994; 90: 1310–1318.Google Scholar
3. Taliercio, CP, Seward, JB, Driscoll, DJ, Fischer, LD, Gersh, BJ, Tajik, AJ. Idiopathic dilated cardiomyopathy in the young: clinical profile and natural history. J Am Coll Cradiol 1985; 6: 1126–1131.Google Scholar
4. Assmus, B, Honold, J, Schachinger, V, et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006; 335: 1222–1232.Google Scholar
5. Schachinger, V, Erbs, S, Elsasserv, A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355: 1210–1221.Google Scholar
6. Rupp, S, Bauer, J, Tonn, T, et al. Intracoronary administration of autologous bone marrow-derived progenitor cells in a critically ill two-yr-old child with dilated cardiomyopathy. Pediatr Transplant 2009; 13: 620–623.CrossRefGoogle Scholar
7. Perin, EC, Dohmann, HF, Borojevic, R, et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 2003; 107: 2294–2302.Google Scholar
8. Lange, R, Vogt, M, Horer, J, et al. Long-term results of repair of anomalous origin of the left coronary artery from the pulmonary artery. Ann Thorac Surg 2007; 83: 1463–1471.Google Scholar